These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 8083697)

  • 1. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
    Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
    Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
    Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
    Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
    Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
    Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
    Winer EP; Chu L; Spicer DV
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.
    Vokes EE; Rosenberg RK; Jahanzeb M; Craig JB; Gralla RJ; Belani CP; Jones SE; Bigley JW; Hohneker JA
    J Clin Oncol; 1995 Mar; 13(3):637-44. PubMed ID: 7533824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
    Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
    Vokes EE; Rosenberg R; Jahanzeb M; Craig J; Gralla R; Belani C; Jones S; Bigley J; Hohneker J
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PubMed ID: 7973767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
    Crawford J; O'Rourke MA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.